Skip to main content
. 2015 Aug 28;21(32):9526–9533. doi: 10.3748/wjg.v21.i32.9526

Table 5.

Main strategies of interferon-free antiviral combinations in liver transplant candidates and recipients with chronic hepatitis C virus infection

Antiviral scheme (duration) Antiviral activity
SOF + RBV (× 12 or 24 wk) Genotype 2 or 3 (perhaps 5, 6)
SOF + Simeprevir ± RBV (× 12 or 24 wk) Genotypes 1, 4
SOF + Daclatasvir ± RBV (× 12 or 24 wk) Genotypes 1, 3, 4
Ledipasvir/SOF ± RBV (× 12-24 wk) Genotypes 1, 3, 4, 6
Paritaprevir/Ritonavir/Ombitasvir + Dasabuvir ± RBV (× 12 or 24 wk) Genotype 1
Paritaprevir/Ritonavir/Ombitasvir ± RBV (× 12 or 24 wk) Genotype 4

SOF: Sofosbuvir; RBV: Ribavirin.